Resources
Related Tags:
GlaxoSmithKline Plc. (925 results)
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Phase Forward Customer GSK Wins Prestigious Wall Street Journal Technology Innovation Award
- Software System, Co-Developed by GSK and Phase Forward Lincoln Safety Group, Helps to Predict Safety Issues in Early-Stage Pharmaceutical Research WALTHAM, Mass. -- Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today congratulated its customer GSK on winning a 2008...
- Research articles 2008-10-27
- Cytokinetics Announces Interim Clinical Trial Data Relating to CK-1827452 Presented at the European Society of Cardiology Congress 2008
- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that additional interim results from an ongoing Phase IIa clinical trial of CK-1827452 were presented as a poster presentation at the European Society of Cardiology ESC Congress 2008, at the Messe München GmbH in Munich, Germany. The trial is evaluating an intravenous formulation...
- Research articles 2008-09-02
- Cytokinetics Announces Clinical Trials Data Relating to CK-1827452 to Be Presented at the European Society of Cardiology Congress 2008
- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that additional interim results from an ongoing Phase IIa clinical trial of CK-1827452 are scheduled to be presented as a poster presentation at the European Society of Cardiology ESC Congress 2008, to be held August 30-September 3, 2008 at the Messe München GmbH in...
- Research articles 2008-08-25
- AHF Blasts GlaxoSmithKline Print Ads That Promote Fear of HIV Treatment
- As Reported in Today's Wall Street Journal, AHF Says Recent GSK Ad Campaign is Attempt to Maintain Market Share without Regard for Patient Health; Asks HHS to Step Up Oversight in Light of FDA's Failure to Do So LOS ANGELES -- AIDS Healthcare Foundation AHF, the largest non-profit AIDS...
- Research articles 2008-08-25
- GlaxoSmithKline urges Kenya to block fake medicines
- NAIROBI AFP — British pharmaceuticals giant GlaxoSmithKline on Monday urged the Kenyan government to crack down on imports of fake medicines, which account for a third of the country's drugs trade. GSK's east Africa chief John Musunga said although his firm had no problem with parallel trade -- importation...
- Research articles 2008-04-14
- European stocks bounce back
- LONDON AFP — Europe's main stock markets rebounded on Tuesday as bargain hunters snapped up cheap shares, following recent sharp losses, amid fresh takeover and company earnings news, dealers said. London's FTSE 100 index of leading blue-chip shares jumped 1.65 percent to 6,308.30 points nearing the half-way stage. ...
- Research articles 2007-07-31
- Controversy spikes over anti-diabetes drug Avandia
- WASHINGTON AFP — Controversy over diabetes drug Avandia heated up Wednesday as experts pointed to studies linking it to greater heart attack risk, while a GSK study claimed rosiglitazone is safe. The GlaxoSmithKline study published online Tuesday by the New England Journal of Medicine NEJM gave preliminary results of...
- Research articles 2007-06-06
- GlaxoSmithKline Responds to Press Release from Senate Committee on Finance About Avandia.
- M2 PRESSWIRE-22 May 2007-ExplorationInvestor: GlaxoSmithKline Responds to Press Release from Senate Committee on Finance About AvandiaC1994-2007 M2 COMMUNICATIONS LTD RDATE:22052007 Exploration Investor strives to provide you with outstanding market results. We will be your number one resource for all your small...
- Research articles 2007-05-22
- Cytokinetics Announces Clinical Trials Data to Be Presented at the 2007 Annual Meeting of the American Society of Clinical Oncology
- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that three abstracts summarizing data from clinical trials relating to its oncology program will be presented at the 2007 Annual Meeting of the American Society of Clinical Oncology ASCO in Chicago, IL, June 1-5, 2007. Two of these abstracts relate to clinical trials...
- Research articles 2007-05-18
- Ranbaxy-GSK to develop respiratory drug.
- Apr. 4--NEW DELHI -- Ranbaxy will develop a respiratory inflammation drug in collaboration GlaxoSmithKline GSK, as part of their new multi-year R&D agreement, a Ranbaxy release on Monday said. Ranbaxy could get up to $100 million in potential milestone payments for a product developed by it...
- Research articles 2007-04-04
- Ribena Vitamin C claims 'may have misled consumers'.
- M2 PRESSWIRE-21 March 2007-ACCC: Ribena Vitamin C claims 'may have misled consumers'C1994-2007 M2 COMMUNICATIONS LTD RDATE:21032007 Claims about the Vitamin C content of Ribena blackcurrant fruit drink products* may have misled consumers, its manufacturer GlaxoSmithKline Australia Pty Limited, has admitted. ...
- Research articles 2007-03-21
- GSK culls pipeline.
- Shares in GlaxoSmithKline GSK dipped after it axed 11 products from its mid-stage pipeline. The drug giant has dropped a thrombosis drug, a diabetes product and four cancer drugs. Andrew Baum, analyst at investment bank Morgan Stanley, says this will slice $1.3bn (GBP673m) off revenue from...
- Research articles 2007-03-09
- Pharma giant's drug tests on Russian children challenged
- MOSCOW AFP — Russian senators called on Friday for an investigation into a vaccine trial by pharmaceutical giant GlaxoSmithKline GSK which local prosecutors say was conducted illegally on children by a clinic in Volgograd region. "We cannot remain indifferent to this because it involves children, and in our view...
- Research articles 2007-03-02
- Tax Analysts obtains Glaxo APA.
- Byline: Audrey Nutt Feb 05, 2007 (Tax Notes International - ABIX via COMTEX) -- GlaxoSmithKline GSK has settled its transfer pricing dispute with the US Internal Revenue Service for $A3.4bn. The case related to the appropriate pricing of GSK's drug Zantac. However the decision...
- Research articles 2007-02-05
- CNS, Inc. Reports Strong Second Quarter Revenue and Earnings Growth
- * Second quarter sales increased by 37% versus the prior year quarter. * Earnings per share increased 56% versus the prior year quarter. * Breathe Right([R]) domestic sales increased 24% driven by new advertising campaigns. * FiberChoice([R])sales increased 87% driven by two new products. * Breathe...
- Research articles 2006-11-02
- GlaxoSmithKline buys US group CNS for 566 million dollars
- LONDON AFP — Pharmaceutical group GlaxoSmithKline GSK announced a deal to buy US consumer healthcare group CNS for 566 million dollars (449 million euros). The transaction, which is subject to regulatory approvals, is expected to close by early 2007, GSK said in a statement to the London Stock Exchange. "GlaxoSmithKline...
- Research articles 2006-10-09
- STOCK ALERT Newsletter Reports Outstanding June Alerts.
- M2 PRESSWIRE-16 June 2006-StockHeadquarters.com: STOCK ALERT Newsletter Reports Outstanding June AlertsC1994-2006 M2 COMMUNICATIONS LTD RDATE:16062006 StockHeadquarters.com, the newsletter known for making stock alerts to its subscribers just days or weeks prior to big surges in the stock price reports that...
- Research articles 2006-06-16
- GSK to offer close to 16 billion dollars for Pfizer unit: sources
- LONDON AFP — Pharmaceutical group GlaxoSmithKline GSK is planning to offer close to 16 billion dollars (12.49 billion euros) for the consumer health care business of its US rival Pfizer, industry sources have said. Sources told AFX News, AFP's financial newswire subsidiary, that GSK, which is based in Britain,...
- Research articles 2006-06-02
- GSK Names New R&D Head and Wyeth to Present at the Merrill Lynch 2006 Global Pharmaceutical, Biotechnology and Medical Device Conference.
- M2 PRESSWIRE-7 February 2006-US Financial Network: GSK Names New R&D Head and Wyeth to Present at the Merrill Lynch 2006 Global Pharmaceutical, Biotechnology and Medical Device ConferenceC1994-2006 M2 COMMUNICATIONS LTD RDATE:07022006 City of Industry, CA - Pharmaceuticals industry news provided by...
- Research articles 2006-02-07
- GlaxoSmithKline stops trial of HIV drug on safety concern
- LONDON AFP — British pharmaceuticals giant GlaxoSmithKline said that it had terminated trials of the HIV inhibitor, Aplaviroc, "to protect the safety and health of patients." GSK took the decision after a patient in one of its so-called "Phase 3" trials experienced liver problems. "Based on a review...
- Research articles 2005-10-25
- << Previous
- page 1 of 4
- Next >>
Content Types
Refining Tags
- Jim Edwards (29 results)
- GlaxoSmithKline Plc. (17 results)
- Finance (17 results)
- Marketing (15 results)
- Sales (12 results)
- Government (12 results)
- Healthcare (12 results)
- Sales Strategy (9 results)
- Agence France-Presse (9 results)
- Patient (8 results)
- Federal Government (8 results)
- FDA (8 results)
- R&D (8 results)
- Software (6 results)
- Business Operations (6 results)
- Investment (6 results)
- Pfizer Inc. (6 results)
- Sales Force Management (5 results)
- Research & Development (5 results)
- Human Resources (5 results)
- stock (4 results)
- Manufacturing (4 results)
- Layoff (4 results)
- Revenue (4 results)
- London (3 results)
- Advertisement (3 results)
- Pricing (3 results)
- Marketing Research (3 results)
- shareholder (3 results)
- Cytokinetics (3 results)
- Vaccine (3 results)
- Financial (3 results)
- Patent (3 results)
- Pharmaceutical Company (3 results)
- Workforce Management (3 results)
- John Maas (3 results)
- Financial Times (3 results)
- Job (3 results)
- Benefits (3 results)
- Operational Accounting (3 results)
